Trastuzumab-related subclinical cardiotoxicity in patients with early stage HER2-positive breast cancer: A retrospective single-center cohort study.

被引：0
|
作者：
Aseyev, Olexiy
Rushton-Marovac, Moira
Crawley, Freya L.
Johnson, Christopher
Dent, Susan Faye
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.10123
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10123
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Douchet, G.
    Richard, Sandrine
    ONCOLOGIE, 2018, 20 (01) : 43 - 44
  • [42] Efficacy and safety of neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab in patients with HER2-positive early breast cancer - A retrospective study
    Koudsi, L.
    Hockaday, C.
    Levitt, N.
    Tuthill, M.
    Roux, R.
    Lord, S.
    Chiramel, J.
    CLINICAL ONCOLOGY, 2025, 38
  • [43] Optimal duration of trastuzumab for early HER2-positive breast cancer
    Specht, Jennifer M.
    Davidson, Nancy E.
    LANCET, 2017, 389 (10075): : 1167 - 1168
  • [44] Trastuzumab-induced cardiotoxicity and hypertension among racially and ethnically diverse patients with HER2-positive early-stage breast cancer.
    Chen, Monica F.
    Manson, Daniel K.
    Yuan, Ariel
    Crew, Katherine D.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] Risk of trastuzumab-related cardiotoxicity in early breast cancer patients in real-world setting
    Xue Jian
    Zhang Xiaozhong
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (16) : C102 - C102
  • [46] Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer
    Otoya, Iris
    Valdiviezo, Natalia
    Morante, Zaida
    Calle, Cindy
    Ferreyra, Yomali
    Huarcaya-Chombo, Norma
    Polo-Mendoza, Gabriela
    Castaneda, Carlos
    Vidaurre, Tatiana
    Neciosup, Silvia P.
    Calderon, Monica J.
    Gomez, Henry L.
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2024, 2024
  • [47] Efficacy and safety analysis of a docetaxel-plus-trastuzumab regimen in patients with early-stage HER2-positive breast cancer: a retrospective single-arm study
    Yao, Jia
    Zhang, Yaqun
    Chen, Mingyi
    Yamashita, Toshinari
    Liu, Yu
    Zheng, Shusen
    GLAND SURGERY, 2025, 14 (02) : 219 - 227
  • [48] Exploring Therapeutic Challenges in Patients with HER2-Positive Breast Cancer-A Single-Center Experience
    Coca, Ramona
    Moisin, Andrei
    Coca, Rafaela
    Diter, Atasie
    Racheriu, Mihaela
    Tanasescu, Denisa
    Popa, Carmen
    Cerghedean-Florea, Maria-Emilia
    Boicean, Adrian
    Tanasescu, Ciprian
    LIFE-BASEL, 2024, 14 (08):
  • [49] Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients
    Tervonen, Hanna E.
    Daniels, Benjamin
    Tang, Monica
    Preen, David B.
    Pearson, Sallie-Anne
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (06) : 812 - 820
  • [50] Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis
    Collova, Elena
    Ferzi, Antonella
    Scandurra, Giuseppa
    Aurilio, Gaetano
    Torri, Valter
    Porcu, Luca
    Sano, Maria Vita
    Taibi, Eleonora
    Foglietta, Jennifer
    Generali, Daniele
    Andreis, Daniele
    Dazzani, Maria Chiara
    Bramati, Annalisa
    Marcon, Ilaria
    Atzori, Francesco
    Cinieri, Saverio
    Tondulli, Luca
    Grasso, Donatalla
    Nole, Franco
    Petrella, Maria Cristina
    Gori, Stefania
    La Verde, Nicla
    TUMORI, 2014, 100 (04) : 426 - 431
12345